Log in

United Therapeutics Stock Price, News & Analysis (NASDAQ:UTHR)

+0.47 (+0.58 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
Now: $82.14
50-Day Range
MA: $81.73
52-Week Range
Now: $82.14
Volume287,310 shs
Average Volume466,003 shs
Market Capitalization$3.60 billion
P/E Ratio6.13
Dividend YieldN/A
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:UTHR



Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$14.44 per share
Book Value$63.98 per share


Net Income$589.20 million


Market Cap$3.60 billion
Next Earnings Date10/30/2019 (Estimated)

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, July, 31st. The biotechnology company reported $4.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $2.40 by $2.26. The biotechnology company earned $373.60 million during the quarter, compared to analyst estimates of $331.78 million. United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

10 equities research analysts have issued 12 month price targets for United Therapeutics' shares. Their forecasts range from $90.00 to $273.00. On average, they anticipate United Therapeutics' share price to reach $125.30 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price. View Analyst Price Targets for United Therapeutics.

What is the consensus analysts' recommendation for United Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

What are Wall Street analysts saying about United Therapeutics stock?

Here are some recent quotes from research analysts about United Therapeutics stock:
  • 1. According to Zacks Investment Research, "United Therapeutics beat on both earnings and sales in Q2. It holds a strong position in the PAH market. Demand for its treprostinil medicines — Remodulin, Tyvaso and Orenitram — remains strong despite generic concerns and competitive pressure. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Moreover, the company bought several new product candidates in 2018 to strengthen its pipeline. However, competition in the PAH market is increasing. Also, two of its biggest products — Remodulin and Adcirca —lost exclusivity in 2018. Generic versions of both the drugs have been launched, which could significantly erode the drugs’ sales in 2019. The stock has also underperformed the industry this year so far" (8/14/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $95/share is based on an equally weighted composite of (a) $98/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $5.78 discounted back to and (b) an NPV of $92/share, discount rate 12.5%, growth rate -2%." (11/1/2018)

Has United Therapeutics been receiving favorable news coverage?

News articles about UTHR stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. United Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for United Therapeutics.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), General Electric (GE), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Allergan (AGN), NVIDIA (NVDA), CytoDyn (CYDY), Skyworks Solutions (SWKS) and Johnson & Johnson (JNJ).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Greylin Investment Mangement Inc. (0.41%), Commerzbank Aktiengesellschaft FI (0.09%), Nisa Investment Advisors LLC (0.05%), Pacer Advisors Inc. (0.04%), Denali Advisors LLC (0.02%) and Envestnet Asset Management Inc. (0.02%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC, Robeco Institutional Asset Management B.V., Fox Run Management L.L.C., Sterling Investment Advisors Ltd., Meeder Asset Management Inc., Sawyer & Company Inc, Commerzbank Aktiengesellschaft FI and Wedbush Securities Inc.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

Which major investors are buying United Therapeutics stock?

UTHR stock was bought by a variety of institutional investors in the last quarter, including Greylin Investment Mangement Inc., Pacer Advisors Inc., Oakbrook Investments LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, Envestnet Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $82.14.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $3.60 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.View Additional Information About United Therapeutics.

What is United Therapeutics' official website?

The official website for United Therapeutics is http://www.unither.com/.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]

MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  436 (Vote Outperform)
Underperform Votes:  584 (Vote Underperform)
Total Votes:  1,020
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel